AnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares Fall
The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, often referred to as eczema.
Hosted on MSN20m
AnaptysBio Stock Down as Eczema Study Fails to Meet GoalsShares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the ...
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...
Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing ...
In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research Report) to a Hold, with a price target of ...
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in ...
Anaptys Bio (NASDAQ:ANAB) stock plunged 33% Wednesday after the company said it was scrapping further development of its drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback